

# Bouthaina S Dabaja

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2982079/publications.pdf>

Version: 2024-02-01

150  
papers

3,480  
citations

159358

30  
h-index

161609

54  
g-index

151  
all docs

151  
docs citations

151  
times ranked

4187  
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessment of Lymphoma and Other Hematologic Malignancies Training Needs Among Radiation Oncology Residents: a Brief Report. <i>Journal of Cancer Education</i> , 2023, 38, 201-205.	0.6	2
2	MALT lymphoma of the tongue: An unusual site that may present a diagnostic challenge. <i>Annals of Diagnostic Pathology</i> , 2022, 56, 151841.	0.6	2
3	NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 322-334.	2.3	35
4	Treating Leukemia in the Time of COVID-19. <i>Acta Haematologica</i> , 2021, 144, 132-145.	0.7	57
5	Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria. <i>Leukemia and Lymphoma</i> , 2021, 62, 1057-1065.	0.6	4
6	Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. <i>British Journal of Haematology</i> , 2021, 192, 560-567.	1.2	9
7	MALT Lymphoma of the Urinary Bladder Shows a Dramatic Female Predominance, Uneven Geographic Distribution, and Possible Infectious Etiology. <i>Research and Reports in Urology</i> , 2021, Volume 13, 49-62.	0.6	4
8	Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up. <i>Blood Cancer Journal</i> , 2021, 11, 17.	2.8	3
9	Radiation and CAR T-cell Therapy in Lymphoma: Future Frontiers and Potential Opportunities for Synergy. <i>Frontiers in Oncology</i> , 2021, 11, 648655.	1.3	19
10	Long-term follow-up of salvage therapy using a combination of inotuzumab ozogamicin and mini-“hyper-CVD with or without blinatumomab in relapsed/refractory Philadelphia chromosome-“negative acute lymphoblastic leukemia. <i>Cancer</i> , 2021, 127, 2025-2038.	2.0	24
11	Post-transplantation donor-derived Sezary syndrome in a patient with <sc>A91V </sc>PRF1 </i> variant hemophagocytic lymphohistiocytosis. <i>American Journal of Hematology</i> , 2021, 96, E350-E353.	2.0	2
12	Modern Radiation Therapy for Extranodal Nasal-Type NK/T-cell Lymphoma: Risk-Adapted Therapy, Target Volume, and Dose Guidelines from the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1064-1081.	0.4	26
13	Primary Mediastinal B Cell Lymphoma in the Positron-Emission Tomography Era Executive Summary of the American Radium Society Appropriate Use Criteria. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 36-44.	0.4	6
14	The impact of cell-of-origin, MYC/Bcl-2 dual expression and <i>MYC</i> rearrangement on disease relapse among early stage diffuse large B-cell lymphoma patients treated with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 1361-1369.	0.6	4
15	Secondary central nervous system diffuse large cell lymphoma: an opportunity for radiation therapy to improve outcomes. <i>Leukemia and Lymphoma</i> , 2021, 62, 1-4.	0.6	5
16	Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma. <i>Blood</i> , 2021, 138, 2463-2463.	0.6	0
17	Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. <i>Blood</i> , 2021, 138, 4536-4536.	0.6	0
18	Phase II Trial of Response Adapted Ultra Low Dose (ULD) Orbital Radiation Therapy for Indolent B Cell Lymphoma. <i>Blood</i> , 2021, 138, 3526-3526.	0.6	0

#	ARTICLE	IF	CITATIONS
19	Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function. <i>Leukemia and Lymphoma</i> , 2020, 61, 171-175.	0.6	14
20	Would Negative Interim PET Be Enough to Omit Radiation in Patients With Early Hodgkin Lymphoma? The Answer Is No. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 16-17.	0.4	0
21	Decreased heart dose with deep inspiration breath hold for the treatment of gastric lymphoma with IMRT. <i>Clinical and Translational Radiation Oncology</i> , 2020, 24, 79-82.	0.9	10
22	Ibrutinib-based therapy for the treatment of marginal zone lymphoma with central nervous system involvement. <i>Leukemia and Lymphoma</i> , 2020, 61, 2980-2984.	0.6	3
23	Radiation Oncology Strategies to Flatten the Curve During the Coronavirus Disease 2019 (COVID-19) Pandemic: Experience From a Large Tertiary Cancer Center. <i>Advances in Radiation Oncology</i> , 2020, 5, 567-572.	0.6	12
24	Effect of Deep Inspiration Breath Hold on Normal Tissue Sparing With Intensity Modulated Radiation Therapy Versus Proton Therapy for Mediastinal Lymphoma. <i>Advances in Radiation Oncology</i> , 2020, 5, 1255-1266.	0.6	11
25	Assessment of Radiation Doses Delivered to Organs at Risk Among Patients With Early-Stage Favorable Hodgkin Lymphoma Treated With Contemporary Radiation Therapy. <i>JAMA Network Open</i> , 2020, 3, e2013935.	2.8	8
26	Two distinct prognostic groups in advanced-stage Hodgkin lymphoma revealed by the presence and site of bulky disease. <i>Blood Advances</i> , 2020, 4, 2064-2072.	2.5	6
27	Mitigating the impact of COVID-19 on oncology: Clinical and operational lessons from a prospective radiation oncology cohort tested for COVID-19. <i>Radiotherapy and Oncology</i> , 2020, 148, 252-257.	0.3	20
28	The Challenges of Applying Radiation in Primary Central Nervous System Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 398-400.	0.4	5
29	Daily computed tomography image guidance: Dosimetric advantages outweigh low-dose radiation exposure for treatment of mediastinal lymphoma. <i>Radiotherapy and Oncology</i> , 2020, 152, 14-18.	0.3	3
30	Partial omission of bleomycin for early-stage Hodgkin lymphoma patients treated with combined modality therapy: Does incomplete ABVD lead to inferior outcomes?. <i>EJHaem</i> , 2020, 1, 272-276.	0.4	5
31	New paradigm for radiation in multiple myeloma: lower yet effective dose to avoid radiation toxicity. <i>Haematologica</i> , 2020, 105, e355-e357.	1.7	10
32	Imaging Surveillance of Limited-stage Classic Hodgkin Lymphoma Patients After PET-CT-documented First Remission. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 533-541.	0.2	2
33	High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC). <i>Blood</i> , 2020, 136, 32-33.	0.6	0
34	Association of Epstein-Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin's Lymphoma. <i>Blood</i> , 2020, 136, 37-38.	0.6	0
35	Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2020, 136, 22-22.	0.6	0
36	Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. <i>Blood</i> , 2020, 136, 17-18.	0.6	0

#	ARTICLE	IF	CITATIONS
37	Comparison of Hyper-CVAD Plus Ofatumumab to Hyper-CVAD Plus Rituximab in Patients with Newly Diagnosed Philadelphia Chromosome-Negative CD20-Positive B-Cell Acute Lymphoblastic Leukemia: A Propensity Score Analysis. <i>Blood</i> , 2020, 136, 42-43.	0.6	0
38	Role of Allogeneic Stem Cell Transplant (ASCT) in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blin): Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 39-41.	0.6	0
39	Association of Smoking with Advanced Stage and Survival Outcomes in Classic Hodgkin's Lymphoma. <i>Blood</i> , 2020, 136, 34-35.	0.6	0
40	Association of Vitamin D Deficiency with Inferior Treatment Outcomes in Patients with Newly Diagnosed Classic Hodgkin Lymphoma: MD Anderson Cancer Center Experience. <i>Blood</i> , 2020, 136, 27-28.	0.6	1
41	Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 45-47.	0.6	0
42	Sequential Combination of Inotuzumab Ozogamicin (InO) with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab (Blin) As Salvage Therapy for Patients (Pts) with Acute Lymphoblastic Leukemia (ALL) in First Relapse. <i>Blood</i> , 2020, 136, 36-38.	0.6	0
43	Brentuximab Vedotin with Chemotherapy in Frontline Treatment of Classic Hodgkin Lymphoma Nodular Sclerosis Syncytial Variant. <i>Blood</i> , 2020, 136, 28-29.	0.6	0
44	Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. <i>Blood</i> , 2020, 136, 27-28.	0.6	0
45	Prognostic Value of Delta Lymphocyte Index (DLI) in Patients with Large B-Cell Lymphoma (LBCL) Treated with Chimeric Antigen Receptor (CAR) T-Cell Therapy. <i>Blood</i> , 2020, 136, 23-24.	0.6	0
46	Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. <i>Blood</i> , 2020, 136, 40-41.	0.6	0
47	Real Life Treatment Alterations of Frontline Therapies in Classic Hodgkin's Lymphoma. <i>Blood</i> , 2020, 136, 23-24.	0.6	0
48	CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study. <i>Blood</i> , 2020, 136, 23-25.	0.6	1
49	Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma. <i>Leukemia and Lymphoma</i> , 2019, 60, 3258-3265.	0.6	1
50	Multi-institutional Investigation: Circulating CD4:CD8 ratio is a prognosticator of response to total skin electron beam radiation in mycosis fungoides. <i>Radiotherapy and Oncology</i> , 2019, 131, 88-92.	0.3	6
51	Postoperative Radiotherapy for Multiple Myeloma of Long Bones: Should the Entire Rod Be Treated?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e465-e469.	0.2	7
52	Rainbow IMRT and Volumetric Imaging for Anterior Mesenteric Targets. <i>Practical Radiation Oncology</i> , 2019, 9, 147-152.	1.1	0
53	Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 447-455.	0.4	31
54	Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 381-389.	0.2	3

#	ARTICLE	IF	CITATIONS
55	Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy. <i>Leukemia and Lymphoma</i> , 2019, 60, 2432-2440.	0.6	2
56	Emerging Treatment Strategies for Primary Breast Extranodal Marginal Zone Lymphoma of Mucosa-associated Lymphoid Tissue. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 244-250.	0.2	11
57	A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma. <i>Scientific Reports</i> , 2019, 9, 1322.	1.6	62
58	Frontline antibiotic therapy for early-stage <i>Helicobacter pylori</i> negative gastric MALT lymphoma. <i>American Journal of Hematology</i> , 2019, 94, E150-E153.	2.0	7
59	Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood Advances</i> , 2019, 3, 1356-1367.	2.5	12
60	Primary cutaneous CD4+ small-to medium-sized pleomorphic T-cell lymphoproliferative disorder in a pediatric patient successfully treated with low-dose radiation. <i>Pediatric Dermatology</i> , 2019, 36, e23-e26.	0.5	4
61	Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e51-e61.	0.2	7
62	Post-ABVD biopsy results, and not post-ABVD FDG-PET results, predict outcome in early-stage Hodgkin lymphoma: response to Adams and Kwee. <i>British Journal of Haematology</i> , 2019, 184, 292-293.	1.2	0
63	Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 1609-1609.	0.6	6
64	Coronary Artery Dose-Volume Parameters Predict Risk of Calcification After Radiation Therapy. <i>Journal of Cardiovascular Imaging</i> , 2019, 27, 268.	0.2	30
65	Maintenance Rituximab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) in the First Line Setting or at Relapse. <i>Blood</i> , 2019, 134, 5291-5291.	0.6	0
66	Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1602-1609.	2.0	15
67	Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 1146-1154.	0.4	15
68	Omitting cardiophrenic lymph nodes in the treatment of patients with Hodgkin lymphoma via modified involved-site radiation therapy. <i>Leukemia and Lymphoma</i> , 2018, 59, 2650-2659.	0.6	2
69	Pre-treatment neutrophil/lymphocyte ratio and platelet/lymphocyte ratio are prognostic of progression in early stage classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 545-549.	1.2	38
70	Bone Marrow Involvement in Patients With Nodular Lymphocyte Predominant Hodgkin Lymphoma. <i>American Journal of Surgical Pathology</i> , 2018, 42, 492-499.	2.1	14
71	Primary breast diffuse large B-cell lymphoma: treatment strategies and patterns of failure. <i>Leukemia and Lymphoma</i> , 2018, 59, 2896-2903.	0.6	12
72	Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 530-540.	0.4	23

#	ARTICLE	IF	CITATIONS
73	Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma. <i>American Journal of Hematology</i> , 2018, 93, 91-99.	2.0	74
74	Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e41-e50.	0.2	17
75	Deep-Inspiration Breath-Hold Intensity Modulated Radiation Therapy to the Mediastinum for Lymphoma Patients: Setup Uncertainties and Margins. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 254-262.	0.4	13
76	Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation. <i>Blood</i> , 2018, 131, 84-94.	0.6	78
77	Coincident primary breast lymphoma and gastrointestinal stromal tumor: case series and molecular mechanisms. <i>Oncotargets and Therapy</i> , 2018, Volume 11, 8937-8942.	1.0	2
78	Positron emission tomography-computed tomography predictors of progression after DA-R-EPOCH for PMBCL. <i>Blood Advances</i> , 2018, 2, 1334-1343.	2.5	23
79	Radiotherapy in Patients with Mycosis Fungoides and Central Nervous System Involvement. <i>Case Reports in Oncology</i> , 2018, 11, 721-728.	0.3	1
80	Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 639-646.	0.6	9
81	Using benchmarked lung radiation dose constraints to predict pneumonitis risk: Developing a nomogram for patients with mediastinal lymphoma. <i>Advances in Radiation Oncology</i> , 2018, 3, 372-381.	0.6	6
82	Proton therapy for adults with mediastinal lymphomas: the International Lymphoma Radiation Oncology Group guidelines. <i>Blood</i> , 2018, 132, 1635-1646.	0.6	86
83	Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2017, 58, 2833-2844.	0.6	13
84	Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. <i>Blood</i> , 2017, 130, 472-477.	0.6	65
85	Effectiveness of low-dose radiation for primary cutaneous anaplastic large cell lymphoma. <i>Advances in Radiation Oncology</i> , 2017, 2, 363-369.	0.6	9
86	Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. <i>American Journal of Hematology</i> , 2017, 92, 924-928.	2.0	17
87	Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma. <i>Head and Neck</i> , 2017, 39, 1095-1100.	0.9	87
88	Daily CT guidance improves target coverage during definitive radiation therapy for gastric MALT lymphoma. <i>Practical Radiation Oncology</i> , 2017, 7, e471-e478.	1.1	13
89	Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. <i>British Journal of Haematology</i> , 2017, 178, 403-412.	1.2	57
90	Cardiac atlas development and validation for automatic segmentation of cardiac substructures. <i>Radiotherapy and Oncology</i> , 2017, 122, 66-71.	0.3	76

#	ARTICLE	IF	CITATIONS
91	A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. <i>Cancer</i> , 2017, 123, 1363-1371.	2.0	18
92	Early-stage Hodgkin lymphoma outcomes after combined modality therapy according to the post-chemotherapy 5-point score: can residual pet-positive disease be cured with radiotherapy alone?. <i>British Journal of Haematology</i> , 2017, 179, 488-496.	1.2	9
93	Primary Cutaneous Peripheral T-Cell Lymphoma in a Sporotrichoid Pattern: A Case Report. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 568-571.	0.6	1
94	Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions. <i>Advances in Radiation Oncology</i> , 2017, 2, 370-380.	0.6	5
95	Craniospinal irradiation prior to stem cell transplant for hematologic malignancies with CNS involvement: Effectiveness and toxicity after photon or proton treatment. <i>Practical Radiation Oncology</i> , 2017, 7, e401-e408.	1.1	21
96	Chemotherapy Response Assessment by FDG-PET-CT in Early-stage Classical Hodgkin Lymphoma: Moving Beyond the Five-Point Deauville Score. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 333-338.	0.4	10
97	Dorsal column myelopathy after intrathecal chemotherapy for leukemia. <i>American Journal of Hematology</i> , 2017, 92, 155-160.	2.0	30
98	Curcumin for the treatment of tumor-stage mycosis fungoides. <i>Dermatologic Therapy</i> , 2017, 30, e12511.	0.8	7
99	Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. <i>Journal of Medical Case Reports</i> , 2016, 10, 209.	0.4	2
100	Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration. <i>American Journal of Hematology</i> , 2016, 91, 894-899.	2.0	15
101	Changes in treatment patterns and impact of radiotherapy for early stage diffuse large B cell lymphoma after Rituximab: A population-based analysis. <i>Radiotherapy and Oncology</i> , 2016, 120, 150-155.	0.3	9
102	Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. <i>Cancer</i> , 2016, 122, 2680-2688.	2.0	48
103	In the Battle Between Protons and Photons for Hematologic Malignancies, the Patient Must Win. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 43-45.	0.4	8
104	Treatment of Early-Stage Unfavorable Hodgkin Lymphoma: Efficacy and Toxicity of 4 Versus 6 Cycles of ABVD Chemotherapy With Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 110-118.	0.4	9
105	Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2612-2618.	0.6	1
106	Does Bleomycin Lung Toxicity Increase the Risk of Radiation Pneumonitis in Hodgkin Lymphoma?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 951-958.	0.4	6
107	Optimizing treatment for nasal NK T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2016, 57, 2487-2488.	0.6	0
108	Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy. <i>JAMA Oncology</i> , 2016, 2, 1065.	3.4	36

#	ARTICLE	IF	CITATIONS
109	Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 122-128.	0.2	12
110	Retrospective Analysis of Prognostic Factors in 187 Cases of Transformed Mycosis Fungoides. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 49-56.	0.2	44
111	Intensive chemoimmunotherapy and bilateral globe irradiation as initial therapy for primary intraocular lymphoma. <i>Neuro-Oncology</i> , 2016, 18, 575-581.	0.6	24
112	Primary cutaneous B-cell lymphoma (non-leg type) has excellent outcomes even after very low dose radiation as single-modality therapy. <i>Leukemia and Lymphoma</i> , 2016, 57, 34-38.	0.6	34
113	Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. <i>Radiation Oncology</i> , 2015, 10, 206.	1.2	1
114	ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2015, 38, 610-620.	0.6	9
115	Radiation for diffuse large B-cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project. <i>Cancer</i> , 2015, 121, 1032-1039.	2.0	39
116	Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: Results of a pooled analysis from 3 phase-II clinical trials. <i>Journal of the American Academy of Dermatology</i> , 2015, 72, 286-292.	0.6	156
117	Radiation Therapy Planning for Early-Stage Hodgkin Lymphoma: Experience of the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 144-152.	0.4	18
118	An unusual case of cytotoxic peripheral T-cell lymphoma. <i>JAAD Case Reports</i> , 2015, 1, 257-260.	0.4	4
119	Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment by 18Fluorodeoxyglucose Positron Emission Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 113-121.	0.4	50
120	Predictors of Radiation Pneumonitis in Patients Receiving Intensity Modulated Radiation Therapy for Hodgkin and Non-Hodgkin Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 175-182.	0.4	110
121	Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1914-1920.	2.0	46
122	Modern Radiation Therapy for Primary Cutaneous Lymphomas: Field and Dose Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 32-39.	0.4	150
123	Benefit of Consolidative Radiation Therapy for Primary Bone Diffuse Large B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 122-129.	0.4	37
124	Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP. <i>Modern Pathology</i> , 2015, 28, 1555-1573.	2.9	48
125	Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 664-670.e2.	0.2	4
126	Long-Term Complete Responses to Combination Therapies and Allogeneic Stem Cell Transplants in Patients With Sézary Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e83-e93.	0.2	37

#	ARTICLE	IF	CITATIONS
127	Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM. <i>Blood</i> , 2015, 126, 1980-1980.	0.6	1
128	Clinical Characteristics and Outcomes of Patients with Hodgkin Lymphoma with Central Nervous System Involvement: An International Multicenter Collaboration. <i>Blood</i> , 2015, 126, 3865-3865.	0.6	0
129	Radiation Pneumonitis Risk after Bleomycin Toxicity in Hodgkin Lymphoma Patients. <i>Blood</i> , 2015, 126, 1511-1511.	0.6	0
130	Comprehensive Craniospinal Radiation for Controlling Central Nervous System Leukemia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 1119-1125.	0.4	22
131	ACR Appropriateness Criteria Follow-up of Hodgkin Lymphoma. <i>Journal of the American College of Radiology</i> , 2014, 11, 1026-1033.e3.	0.9	16
132	Radiation Therapy Is an Effective Modality in the Treatment of Mantle Cell Lymphoma, Even in Heavily Pretreated Patients. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2014, 14, 474-479.	0.2	20
133	Dosimetric advantages of a "butterfly" technique for intensity-modulated radiation therapy for young female patients with mediastinal Hodgkin's lymphoma. <i>Radiation Oncology</i> , 2014, 9, 94.	1.2	90
134	Modern Radiation Therapy for Nodal Non-Hodgkin Lymphoma—Target Definition and Dose Guidelines From the International Lymphoma Radiation Oncology Group. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 49-58.	0.4	259
135	Positron Emission Tomography/Computed Tomography Findings During Therapy Predict Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemotherapy Alone but Not in Those Who Receive Consolidation Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 384-391.	0.4	8
136	Double Hit Lymphoma: M.D. Anderson Experience. <i>Blood</i> , 2013, 122, 1776-1776.	0.6	5
137	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 641-641.	0.6	3
138	Either Combined-Modality Or Radiotherapy Alone Provide Favorable Outcome In Stage I-II Mantle Cell Lymphoma: A Report Of 82 Patients From The International Lymphoma Radiation Oncology Group (ILROG). <i>Blood</i> , 2013, 122, 4292-4292.	0.6	1
139	Radiation Therapy Significantly Improves Survival Of Patients With Diffuse Large B-Cell Lymphoma Associated With MYC Translocation: A Report From The International DLBCL Rituximab-CHOP Consortium Program. <i>Blood</i> , 2013, 122, 213-213.	0.6	0
140	The Prognostic Value of Interim PET Scan in Patients with Classical Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 1529-1529.	0.6	5
141	Radiation for Hodgkin's Lymphoma in Young Female Patients: A New Technique to Avoid the Breasts and Decrease the Dose to the Heart. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 503-507.	0.4	36
142	Clinical Implications of PET-Negative Residual Disease At the Completion of Chemotherapy for Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2011, 118, 2695-2695.	0.6	11
143	Continuous Decline in Second Malignancy Occurrence in Patients with Hodgkin Lymphoma; Analysis of 1670 Patients Over the Past 5 Decades. <i>Blood</i> , 2011, 118, 2694-2694.	0.6	0
144	Successful treatment of a free-moving abdominal mass with radiation therapy guided by cone-beam computed tomography: a case report. <i>Journal of Medical Case Reports</i> , 2010, 4, 329.	0.4	5

#	ARTICLE	IF	CITATIONS
145	Outcomes of Nodular Lymphocyte Predominant Hodgkin's Lymphoma (NLPHL) Patients Treated with R-CHOP.. Blood, 2010, 116, 2812-2812.	0.6	24
146	Intensity-modulated radiation therapy (IMRT) of cancers of the head and neck: Comparison of split-field and whole-field techniques. International Journal of Radiation Oncology Biology Physics, 2005, 63, 1000-1005.	0.4	76
147	Adenocarcinoma of the small bowel. Cancer, 2004, 101, 518-526.	2.0	472
148	Primary central nervous system lymphoma: Phase I evaluation of infusional bromodeoxyuridine with whole brain accelerated fractionation radiation therapy after chemotherapy. Cancer, 2003, 98, 1021-1028.	2.0	23
149	Importance of Esophagogastroduodenoscopy in the Evaluation of Non-Gastrointestinal Mucosa-Associated Lymphoid Tissue Lymphoma. Cancer Journal (Sudbury, Mass ), 2003, 9, 321-324.	1.0	19
150	The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer, 2002, 94, 2738-2744.	2.0	55